We are live on ! Find out more
TLSI icon

TriSalus Life Sciences
TLSI

60 hedge funds and large institutions have $44.6M invested in TriSalus Life Sciences in 2025 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

650% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 2

64% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 11

25% more funds holding

Funds holding: 48 → 60 (+12)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less capital invested

Capital invested by funds: $46.8M → $44.6M (-$2.25M)

3.48% less ownership

Funds ownership: 22.7% → 19.22% (-3.5%)

Holders
60
Holders Change
+12
Holders Change %
+25%
% of All Funds
0.79%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
15
Increased
18
Reduced
11
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$1.62M
2
BlackRock
BlackRock
New York
+$778K
3
Goldman Sachs
Goldman Sachs
New York
+$626K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$465K
5
State Street
State Street
Massachusetts
+$361K

Top Sellers

Rank Fund Capital Flow
1
GGHC
Gilder Gagnon Howe & Co
New York
-$215K
2
Morgan Stanley
Morgan Stanley
New York
-$180K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$112K
4
Deutsche Bank
Deutsche Bank
Germany
-$105K
5
UBS Group
UBS Group
Switzerland
-$36.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
1
Nantahala Capital Management
Connecticut
$9.49M +$188K +40,245 +2%
AIC
2
AWM Investment Company
New York
$5.81M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$5.39M +$1.62M +345,186 +42%
GGHC
4
Gilder Gagnon Howe & Co
New York
$4.87M -$215K -45,916 -4%
BlackRock
5
BlackRock
New York
$3.66M +$778K +166,175 +27%
WAP
6
Wealthcare Advisory Partners
Pennsylvania
$2.99M – – –
Alyeska Investment Group
7
Alyeska Investment Group
Illinois
$2.59M – – –
Geode Capital Management
8
Geode Capital Management
Massachusetts
$2.58M +$465K +99,404 +22%
State Street
9
State Street
Massachusetts
$896K +$361K +77,036 +67%
Bank of America
10
Bank of America
North Carolina
$880K +$1.28K +274 +0.1%
Northern Trust
11
Northern Trust
Illinois
$821K +$236K +50,391 +40%
Goldman Sachs
12
Goldman Sachs
New York
$700K +$626K +133,671 +795%
Corient Private Wealth
13
Corient Private Wealth
Florida
$352K +$354K +75,700 New
Squarepoint
14
Squarepoint
New York
$343K +$345K +73,706 New
CAMG
15
CWA Asset Management Group
Florida
$335K +$337K +72,000 New
BCM
16
Bridgeway Capital Management
Texas
$323K -$27.6K -5,900 -8%
WPC
17
White Pine Capital
Minnesota
$278K +$280K +59,733 New
Charles Schwab
18
Charles Schwab
California
$266K +$34.1K +7,293 +15%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$217K +$23K +4,903 +12%
MP
20
MSD Partners
New York
$186K – – –
Millennium Management
21
Millennium Management
New York
$166K +$25.1K +5,359 +18%
CCM
22
Connective Capital Management
California
$153K – – –
Barclays
23
Barclays
United Kingdom
$123K -$16.2K -3,469 -12%
VI
24
Vestcor Inc
New Brunswick, Canada
$109K – – –
CWM
25
Connecticut Wealth Management
Connecticut
$104K – – –
1
2 3

TLSI Hedge Fund Activity: Q3 2025 in Review

60 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in TriSalus Life Sciences (TLSI) for Q3 2025, worth a combined $44.6M — down 4.8% from $46.8M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new TLSI positions and 2 closed out — a net gain of 13 holders — while 18 added to existing stakes and 11 trimmed.

The largest buyer was Vanguard Group, adding an estimated $1.62M. The largest seller was Gilder Gagnon Howe & Co, cutting an estimated $215K.

  • 60 institutional investors held TriSalus Life Sciences (TLSI) as of Q3 2025, up from 48 in Q2 2025.
  • Funds reported $44.6M of TriSalus Life Sciences stock for Q3 2025, down 4.8% quarter-over-quarter.
  • 15 funds opened new TriSalus Life Sciences positions in Q3 2025 and 2 closed out, a net change of +13 holders.
  • The largest TriSalus Life Sciences buyer in Q3 2025 was Vanguard Group, an estimated $1.62M added.
  • The largest TriSalus Life Sciences seller in Q3 2025 was Gilder Gagnon Howe & Co, an estimated $215K sold.

Based on aggregated 13F filings for Q3 2025.